4basebio appoints Dr Jeff Coller to advisory board.

4basebio announced the appointment of Dr Jeff Coller to its strategic advisory board on Monday, as the synthetic DNA specialist scales its technology for mRNA synthesis, AAV vector manufacturing and gene editing applications.

4basebio
15 June 2026 14:02:00

Source: Sharecast

The AIM-traded company said Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University and inaugural director of the RNA Innovation Center, would bring expertise in mRNA stability and translation to support its strategy for producing high-fidelity DNA templates for genetic medicines.

Chief executive Dr Amy Walker said Coller’s discoveries in mRNA stability and translation were “nothing short of transformative for our industry”.

Coller said: “The future of mRNA therapeutics hinges entirely on the quality and scalability of the starting materials.

“4basebio has engineered a truly disruptive approach to synthetic DNA manufacturing that eliminates the legacy challenges of plasmid DNA.”

At 1315 BST, shares in 4basebio were up 4.29% at 547.5p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.